20 completed, 3 recruiting, 2 active not recruiting, 1 not yet recruiting. 8 Phase 3, 7 Phase 1, 5 Phase 2, 4 Phase 4, 3 Not applicable.
Follow Cholestyramine Resin: new trials by email Literature Review of Cholestyramine Resin trials Research Report on Cholestyramine Resin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PFAS Clinical Trial Cholestyramine, Centrum - Environmental Exposure | Phase 2 | Not yet recruiting | Emory University | 300 | 2026-11-01 | 2026-09-23 |
| Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients Cholestyramine Powder - Obesity, Abdominal, Diabetes | Not applicable | Recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2025-03-19 | 2025-03-24 |
| Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer Biospecimen Collection, Cholestyramine, Computed Tomography - Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 19 | 2024-06-10 | 2026-10-20 |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis Frexalimab, Teriflunomide, Placebo infusion - Multiple Sclerosis | Phase 3 | Active not recruiting | Sanofi | 1655 | 2023-12-13 | 2026-07-20 |
| Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies Cholestyramine, Leflunomide, Steroid Therapy - Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm | Phase 1 | Recruiting | City of Hope Medical Center | 18 | 2023-06-16 | 2026-07-08 |
| A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants LOXO-783, Cholestyramine - Healthy | Phase 1 | Completed | Eli Lilly and Company | 21 | 2023-06-07 | 2023-09-26 |
| Efficacy and Safety of Cholestyramine in the Management of Hyperphosphatemia in Adult Hemodialysis Patients Cholestyramine Resin 4000 MG [Questran], Calcium Carbonate 500 MG Oral Tablet - Chronic Kidney Diseases, Hemodialysis Complication | Phase 4 | Completed | Ain Shams University | 80 | 2023-03-30 | 2024-08-06 |
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients Cholestyramine, Leflunomide - Smoldering Plasma Cell Myeloma | Phase 2 | Active not recruiting | City of Hope Medical Center | 27 | 2022-03-07 | 2026-04-30 |
| A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles Cholestyramine Resin - Human Microbiome | Phase 1 | Completed | Seoul National University Hospital | 15 | 2020-05-01 | 2021-03-17 |
| Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g), Elobixibat 10mg + cholestyramine powder placebo, Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g) - Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | Phase 2 | Completed | Yokohama City University | 102 | 2020-01-29 | 2021-11-16 |
| An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia Alirocumab SAR236553 (REGN727), Atorvastatin, Simvastatin - Hypercholesterolemia | Phase 3 | Completed | Sanofi | 18 | 2018-08-31 | 2020-12-29 |
| An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin - Hypercholesterolaemia | Phase 3 | Completed | Sanofi | 153 | 2018-05-31 | 2023-05-06 |
| Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Cholestyramine Powder 4g, Prednisolone, Standard treatment - Hyperthyroidism, Graves Disease | Phase 3 | Unknown | Clinical Research Centre, Malaysia | 135 | 2017-05-11 | 2017-10-05 |
| An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia alirocumab SAR236553 (REGN727), statins, ezetimibe - Hypercholesterolaemia | Phase 2 | Completed | Sanofi | 42 | 2016-09-15 | 2019-09-06 |
| PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs CHOLESTYRAMINE - DIABETES, DIABETIC RETINOPATHY | Phase 4 | Completed | University of Chile | 7 | 2015-01-01 | 2018-02-14 |
| A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers Teriflunomide HMR1726, cholestyramine - Multiple Sclerosis | Phase 1 | Completed | Sanofi | 12 | 2014-05-01 | 2014-08-21 |
| Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia Atorvastatin 20 mg, Cholestyramine 8 g, Omega-3 2g - Hyperlipidemia | Not applicable | Completed | Yonsei University | 58 | 2014-04-03 | 2018-07-18 |
| Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis teriflunomide HMR1726, cholestyramine, charcoal - Multiple Sclerosis | Phase 3 | Completed | Sanofi | 70 | 2013-10-01 | 2015-03-13 |
| A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384 A4250, CRC (A3384), Questran - Orphan Cholestatic Liver Diseases, Primary Biliary Cirrhosis | Phase 1 | Completed | Albireo | 94 | 2013-07-01 | 2024-03-07 |
| Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment Teriflunomide HMR1726, Cholestyramine - Renal Impairment | Phase 1 | Completed | Sanofi | 16 | 2010-11-01 | 2012-03-01 |
Showing 20 of 27. Sign in to see all of them.
Cardiovascular Diseases (4) · Coronary Disease (4) · Diabetes Mellitus (4) · Heart Diseases (4) · Myocardial Ischemia (4) · Hypercholesterolemia (3) · Multiple Sclerosis (3) · Graves Disease (2) · Hyperthyroidism (2) · Alagille Syndrome (1) · Cholestasis, progressive familial intrahepatic 1 (1) · Diabetic Neuropathies (1) · Diabetic Retinopathy (1) · Homozygous Familial Hypercholesterolemia (1) · Hyperlipidemias (1)
Sanofi (7) · National Heart, Lung, and Blood Institute (NHLBI) (4) · City of Hope Medical Center (3) · Louisville Metabolic and Atherosclerosis Research Center (2) · Ain Shams University (1) · Albireo (1) · Centre Hospitalier Universitaire de Nice (1) · Clinical Research Centre, Malaysia (1) · Eli Lilly and Company (1) · Emory University (1) · Seoul National University Hospital (1) · Shiraz University of Medical Sciences (1) · University of Chile (1) · Yokohama City University (1) · Yonsei University (1)
United States (10) · Canada (4) · France (4) · Netherlands (4) · Spain (4) · Brazil (3) · Czechia (3) · Denmark (3) · Germany (3) · Mexico (3) · Russia (3) · South Africa (3) · South Korea (3) · Taiwan (3) · Turkey (Türkiye) (3)
Harold E Bays, MD (2) · Anne Goldberg (1) · Chung Jae Yong, MD, PhD (1) · Dennis Sprecher (1) · Elizabeth Barrett-Connor (1) · Francois Abboud (1) · Frank Ibbott (1) · Frank Sacks (1) · Genell Knatterud (1) · Gerald Cooper (1) · Golamhossein Omrani, M.D. (1) · Ivan Frantz (1) · J. Little (1)
PMID 18946743, PMID 28245873, PMID 29805116, PMID 32331936, PMID 32414298, PMID 32907904, PMID 36325897, PMID 38315470, PMID 39899371, PMID 39910709, PMID 42847113
P30CA033572 (3), 2017 (2), 2015 (1), 2023 (1), R01HL036392 (1)